Clinical research tests new treatments, technology, and clinical practices (developed from translational research) in human participants to evaluate their safety and effectiveness. The OCIG collaborates with UCHealth, various departments within CU School of Medicine, and global pharmaceutical and biotechnological partners to offer a variety of clinical trials. These studies provide patients with access to new treatments or interventions not yet available to the public while helping researchers learn how to improve outcomes for future patients.

To improve survival rates, we are assessing and validating the clinical effectiveness of potential biomarkers, such as non-coding RNA, for the early detection, diagnosis, disease monitoring, and prediction of treatment outcomes of ovarian cancer. These diagnostic and prognostic biomarkers equip clinicians with new, innovative tools to guide treatment decisions that are tailored to the patient's unique genetic, molecular, and cellular characteristics.

OCIG collaborates with UCHealth, various departments within CU School of Medicine, and global pharmaceutical and biotechnological partners to offer a variety of clinical trials. These studies provide patients with access to new treatments or interventions not yet available to the public while helping researchers learn how to improve outcomes for future patients.